Biodistribution and Pharmacokinetics of ¹¹¹In-DTPA-Labelled Pegylated Liposomes After Intraperitoneal Injection

References

• Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intra-venous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950–5.
   PubMed Web of Science ®Google Scholar
• Buchsbaum Hi, Keettel WC. Radioisotopes in treatment of stage la ovarian cancer. Natl Cancer Inst Monogr 1975; 42: 127–8.
   PubMedGoogle Scholar
• Edwards RP, Gooding W, Lembersky BC, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 1997; 15: 3399–407.
   PubMed Web of Science ®Google Scholar
• Hird V. Maraveyas A, Snook D. et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993: 68: 403–6.
   PubMed Web of Science ®Google Scholar
• Francis P. Rowinsky E, Schneider .1, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a gynecologic oncology group pilot study. J Clin Oncol 1995; 13: 2961–7.
   Google Scholar
• Lasic DD, Papahadjopoulos D. Liposomes revisited. Science 1995; 267: 1275–6.
   PubMed Web of Science ®Google Scholar
• Huang SK, Lee K-D, Hong K. Friend DS, Papahadjopoulos D. Microscopic localisation of sterically stabilised liposornes in colon carcinoma-bearing mice. Cancer Res 1992; 52: 5135––43.
   Google Scholar
• Harrington KJ. Liposomat cancer chemotherapy: current clin-ical applications and future prospects. Expert Opin Invest Drugs 2001; 10: 1045–61.
   PubMed Web of Science ®Google Scholar
• Madhavan S. Northfelt DW. Lack of vesicant injury follow-ing extravasationliposomal doxorubicin. J Nail CancerInst 1995; 87: 1556–7.
   Google Scholar
• Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Vile RG, Stewart JSW. Pegylated liposomes have potential as vehicles for intratumoural and subcutaneous drug delivery. Clin Cancer Res 2000; 6: 2528–37.
   PubMed Web of Science ®Google Scholar
• Gonda] JA, Preuss HG, Swartz R. Rahman A. Comparative pharmacological, toxicological and antitumoural evaluation of free and liposome-encapsulated cisplatin in rodents. Eur J Cancer 1993; 29A: 1536–42.
   Google Scholar
• Sharma A, Mayhew E, Bolcsak L. et al. Activity of paclitaxel liposome formulations against human ovarian tumour xeno-grafts. Int J Cancer 1997; 71: 103–7.
   Google Scholar
• Sharma A. Sharma US, Straubinger RM. Paclitaxel-lipo-somes for intracavitary therapy of intraperitoneal P388 leukaemia. Cancer Lett 1996; 107: 265–72.
   Google Scholar
• Vaage J. Donovan D. Mayhew E. Abra R. Huang A. Ther-apy of human ovarian carcinoma xenografts using doxoru-bicin encapsulated in sterically stabilised liposomes. Cancer 1993; 72: 3671–5.
   Google Scholar
• Vadiei K, Siddik ZH. Khokhar AR, al-Baker S. Sampedro F, Perez-Soler R. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato trans-R. R-1,2 diaminocyclohexane plat-Mum (II) and cisplatin given i.v. and i.p. in the rat. Cancer Chemother Pharmacol 1992; 30: 365–9,
   Google Scholar
• Cabanes A, Tzemach D, Goren D, Horowitz AT, Gabizon A. Comparative study of the antitumour activity of free doxoru-bicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res 1998; 4: 499–505.
   Google Scholar
• Delgado G, Potkul RK, Treat JA, et al. A phase I/II study of intraperitoneally administered doxorubicin entrapped in car-diolipin liposomes in patients with ovarian cancer. Am J Obstet Gynecol 1989; 160: 812–7.
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Shin DM, Siddik ZH, et al. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin Cancer Res 1997; 3: 373–9,
   Google Scholar
• Harrington KJ, Rowlinson-Busza G. Syrigos KN, Uster PS, Abra RM, Stewart JSW. 13iodistribution and pharmacokinet-ics of "In-DTPA-labelled pegylated Iiposornes in a human tumour xenograft model: implications for novel targeting strategies. Br J Cancer 2000; 83: 232–8.
   Google Scholar
• Harrington KJ, Mohammadtaghi S. Uster PS, Glass DM, Peters AM, Vile RG, Stewart JSW. Effective targeting of solid tumors in patients with locally advanced cancers by radiola-beled pegylated liposomes. Clin Cancer Res 2001; 7: 243–54.
   Google Scholar
• O'Dwyer PJ, LaCreta F, Hogan M. Rosenblum N, O'Dwyer JL, Comis RL. Pharmacologic study of etoposide and cis-plaint by the intraperitoneal route. J Clin Pharmacol 1991; 31: 253–8.
   Google Scholar
• Malviya VK, Deppe G. Boike G, Young J. Pharmacokinetics of intraperitoneal doxorubicin in combination with systemic cyclophosphamide and cis-platinum in the treatment of stage III ovarian cancer. Gynecol Oncol 1990; 36: 185, 8.
   Google Scholar
• Muggia FM, Hainsworth JD, Jeffers S. et at. Phase 11 study of liposomal doxorubicin in refractory ovarian cancer: antitu-mour activity and toxicity modification by liposomal encapsu-lation. J Cliii Oncol 1997; 15: 987–93.
   Google Scholar
• Markman M, Kennedy A, Webster K, Peterson G. Kulp B. Belinson J. Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinumipaclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000; 78: 369–72.
   Google Scholar
• Gordon AN, Granai CO, Rose PG, et at. Phase II study of liposomal doxorubicin in platinum- and pactitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000: IS: 3093–100.
   Google Scholar
• Kim S. Kim DJ, Howell SB. Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank lipo-somes. Cancer Chemother Pharmacol 1987; 19: 307•–10.
   Google Scholar